Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro

Area of Science:

• Cardiovascular Pharmacology
• Nutritional Biochemistry
• Platelet Physiology

Background:

• Omega-3 polyunsaturated fatty acids (PUFAs), including Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA), possess cardioprotective properties.
• These effects involve modulation of inflammation, platelet activation, endothelial function, and lipid metabolism, notably triglyceride reduction.
• Omega-3 PUFAs are frequently prescribed for hypertriglyceridemia and alongside antiplatelet therapy in cardiovascular disease (CVD) patients.

Purpose of the Study:

• To investigate the combined effects of EPA and DHA with common antiplatelet drugs on platelet aggregation.
• To assess the impact of these combinations on P-selectin and α_IIbβ₃ membrane expression in platelets.
• To determine if synergistic interactions occur between omega-3 PUFAs and antiplatelet agents.

Main Methods:

• In vitro assessment of platelet aggregation induced by arachidonic acid (AA), adenosine diphosphate (ADP), and TRAP-6.
• Evaluation of combinations of DHA or EPA with aspirin, triflusal, ticagrelor, and vorapaxar.
• Measurement of P-selectin and α_IIbβ₃ membrane expression using procaspase-activating compound 1 (PAC-1) binding assays.

Main Results:

• Both DHA and EPA demonstrated dose-dependent inhibition of platelet aggregation.
• DHA enhanced acetylsalicylic acid (ASA) and triflusal efficacy against AA-induced aggregation; EPA boosted ASA's effect.
• EPA combined with ASA and ticagrelor showed increased inhibition of ADP-induced platelet activation; EPA also enhanced antiplatelet drug effects against TRAP-6 activation. Omega-3s inhibited α_IIbβ₃ expression but not P-selectin.
• Combinations did not produce enhanced inhibitory activity beyond the sum of individual effects.

Conclusions:

• DHA and EPA exhibit intrinsic antiplatelet properties and can modulate the efficacy of certain antiplatelet drugs.
• While some combinations show additive effects, synergistic interactions between omega-3 PUFAs and the tested antiplatelet agents were not observed.
• Further research is needed to fully elucidate the clinical implications of omega-3 PUFA and antiplatelet drug co-administration.